Ipragliflozin: Phase IIb data

A double-blind, dose-escalation, U.S. Phase IIb trial in 412 Type II diabetics showed that ipragliflozin significantly and dose-dependently reduced HbA1c from baseline to week 12, the primary endpoint, vs. placebo (p<0.001 for all doses). Specifically, the 300 mg dose of ipragliflozin reduced HbA1c from baseline to week 12 by about 0.8% relative to placebo. Additionally, ipragliflozin led to similar reductions in HbA1c to that of metformin. Ipragliflozin was well tolerated. Patients received 12.5, 50, 150 or 300 mg ipragliflozin, placebo or metformin. ...